Vimarsana.com

Latest Breaking News On - Selecta bioscience - Page 1 : vimarsana.com

Head to Head Review: Takeda Pharmaceutical (NYSE:TAK) vs. Nurix Therapeutics (NASDAQ:NRIX)

Takeda Pharmaceutical (NYSE:TAK – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Volatility and Risk Takeda Pharmaceutical has a beta […]

California
United-states
Japan
Tokyo
San-francisco
Xenetic-biosciences
Leuplin-enantone
Sosei-heptares
Selecta-biosciences
Heidelberg-pharma
Falk-pharma-gmb
Takecab-vocinti

Financial Comparison: Citius Pharmaceuticals (NASDAQ:CTXR) & Takeda Pharmaceutical (NYSE:TAK)

Financial Comparison: Citius Pharmaceuticals (NASDAQ:CTXR) & Takeda Pharmaceutical (NYSE:TAK)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Tokyo
Japan
New-jersey
United-states
Heidelberg-pharma
Falk-pharma
Gattex-revestive
Selecta-bioscience
Sosei-heptares
Adynovate-adynovi
Hemofil-immunate-immunine
Selecta-biosciences

Analyzing WuXi Biologics (Cayman) (OTCMKTS:WXXWY) and Selecta Biosciences (NASDAQ:SELB)

WuXi Biologics (Cayman) (OTCMKTS:WXXWY – Get Free Report) and Selecta Biosciences (NASDAQ:SELB – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Analyst Recommendations This is a summary of […]

Massachusetts
United-states
China
Massachusetts-institute-of-technology
Wuxi
Jiangsu
Watertown
Shenyang
Liaoning
America
Selecta-bioscience
Selecta-biosciences

SVB Leerink Analysts Increase Earnings Estimates for Selecta Biosciences, Inc. (NASDAQ:SELB)

Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) – Research analysts at SVB Leerink upped their Q1 2023 earnings per share (EPS) estimates for shares of Selecta Biosciences in a report released on Tuesday, March 21st. SVB Leerink analyst J. Schwartz now expects that the company will post earnings of ($0.01) per share for the quarter, […]

Selecta-bioscience
Selecta-biosciences
Carsten-brunn
Prudential-financial-inc
Canaccord-genuity-group
Citigroup-inc
Selecta-biosciences-inc
Nasdaq
Pricet-rowe-associates-inc
Beacon-pointe-advisors
Selecta-biosciences-company-profile
Securities-exchange-commission

Zacks: Analysts Expect Selecta Biosciences, Inc. (NASDAQ:SELB) Will Post Quarterly Sales of $19.07 Million

Wall Street analysts forecast that Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) will report $19.07 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Selecta Biosciences’ earnings. The highest sales estimate is $23.15 million and the lowest is $15.00 million. Selecta Biosciences reported sales of […]

Timothyc-barabe
Selecta-bioscience
Selecta-biosciences
Marshall-wace
Zacks-investment-research
Selecta-biosciences-inc
Blackrock-inc
Nanodimension-inc
Nasdaq
Vanguard-group-inc
Wall-street
Get-rating

$18.82 Million in Sales Expected for Selecta Biosciences, Inc. (NASDAQ:SELB) This Quarter

Equities analysts expect that Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) will post $18.82 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Selecta Biosciences’ earnings. The lowest sales estimate is $18.00 million and the highest is $19.65 million. Selecta Biosciences reported sales of $11.05 million […]

Selecta-bioscience
Selecta-biosciences
Zacks-investment-research
Selecta-biosciences-company-profile-get-rating
Nasdaq
Marshall-wace
Management-co
Selecta-biosciences-inc
Healthcare-of-ontario-pension-plan-trust-fund
Nanodimension-inc
Millennium-management
Get-rating

Brokerages Expect Selecta Biosciences, Inc. (NASDAQ:SELB) Will Announce Earnings of -$0.09 Per Share

Equities research analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB – Get Rating) to announce ($0.09) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Selecta Biosciences’ earnings. Selecta Biosciences posted earnings per share of ($0.22) in the same quarter last year, which suggests a positive year-over-year […]

Thomson-reuter
Carsten-brunn
Selecta-bioscience
Selecta-biosciences
Geode-capital-management
Securities-exchange-commission
Zacks-investment-research
Blackrock-inc
Nasdaq
Marshall-wace
Selecta-biosciences-inc
Nanodimension-inc

Seattle DJC.com local business news and data - Business

Seattle DJC.com local business news and data - Business
djc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from djc.com Daily Mail and Mail on Sunday newspapers.

University-of-washington
Washington
United-states
Seattle
Selecta-bioscience
Selecta-biosciences
David-baker
Broad-institute
W-fund
University-of-illinois-at-urbana-champaign
Washington-research-foundation
Orthogonal-biologics

Funding news: Cyrus lands $18M and buys startup developing COVID-19 therapeutic; Spare Labs snags $18M for mobility software

Funding news: Cyrus lands $18M and buys startup developing COVID-19 therapeutic; Spare Labs snags $18M for mobility software
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.

Arkansas
United-states
Japan
Washington
Seattle
Sugar-mountain
Vancouver
British-columbia
Canada
Geeta-vemuri
Selecta-bioscience
Selecta-biosciences

vimarsana © 2020. All Rights Reserved.